Janus Henderson Group PLC Mirati Therapeutics, Inc. Transaction History

Janus Henderson Group PLC

$182 Billion
Q2 2024

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$41.99 - $62.38 $366,614 - $544,639	-8,731 Reduced 29.61%	20,753 $1.22 Million
Q3 2023 Nov 14, 2023	BUY	$27.8 - $45.35 $285,283 - $465,381	10,262 Added 53.39%	29,484 $1.28 Million
Q2 2023 Aug 14, 2023	SELL	$36.13 - $49.49 $578 - $791	-16 Reduced 0.08%	19,222 $694,000
Q1 2023 May 15, 2023	SELL	$36.54 - $54.26 $18.6 Million - $27.6 Million	-508,471 Reduced 96.35%	19,238 $715,000
Q4 2022 Feb 14, 2023	SELL	$41.27 - $98.62 $8.19 Million - $19.6 Million	-198,399 Reduced 27.32%	527,709 $23.9 Million
Q3 2022 Nov 14, 2022	SELL	$59.5 - $86.7 $336,115 - $489,768	-5,649 Reduced 0.77%	726,108 $50.7 Million
Q2 2022 Aug 15, 2022	SELL	$39.16 - $88.71 $8.22 Million - $18.6 Million	-209,946 Reduced 22.29%	731,757 $49.1 Million
Q1 2022 May 16, 2022	BUY	$75.82 - $150.97 $4.07 Million - $8.1 Million	53,635 Added 6.04%	941,703 $77.4 Million
Q4 2021 Feb 14, 2022	SELL	$132.01 - $190.29 $14.5 Million - $20.9 Million	-109,933 Reduced 11.02%	888,068 $130 Million
Q3 2021 Nov 16, 2021	SELL	$132.13 - $177.45 $9.51 Million - $12.8 Million	-71,966 Reduced 6.73%	998,001 $177 Million
Q2 2021 Aug 16, 2021	SELL	$144.0 - $179.73 $12.4 Million - $15.5 Million	-86,196 Reduced 7.46%	1,069,967 $173 Million
Q1 2021 May 17, 2021	BUY	$158.92 - $221.61 $571,158 - $796,466	3,594 Added 0.31%	1,156,163 $198 Million
Q4 2020 Feb 16, 2021	SELL	$162.05 - $240.27 $118 Million - $174 Million	-726,211 Reduced 38.65%	1,152,569 $253 Million
Q3 2020 Nov 16, 2020	SELL	$113.26 - $167.27 $76.1 Million - $112 Million	-671,594 Reduced 26.33%	1,878,780 $312 Million
Q2 2020 Aug 14, 2020	BUY	$72.01 - $120.39 $14.5 Million - $24.3 Million	201,473 Added 8.58%	2,550,374 $291 Million
Q1 2020 May 14, 2020	BUY	$69.78 - $116.21 $27.3 Million - $45.5 Million	391,117 Added 19.98%	2,348,901 $181 Million
Q4 2019 Feb 18, 2020	SELL	$70.76 - $128.86 $3.85 Million - $7 Million	-54,351 Reduced 2.7%	1,957,784 $252 Million
Q3 2019 Nov 14, 2019	BUY	$77.91 - $109.6 $26.1 Million - $36.7 Million	334,596 Added 19.95%	2,012,135 $157 Million
Q2 2019 Jul 31, 2019	SELL	$59.49 - $104.71 $21.3 Million - $37.4 Million	-357,205 Reduced 17.56%	1,677,539 $173 Million
Q1 2019 Apr 30, 2019	BUY	$43.65 - $78.95 $41.7 Million - $75.5 Million	956,022 Added 88.63%	2,034,744 $149 Million
Q4 2018 Feb 06, 2019	BUY	$32.0 - $47.43 $1.69 Million - $2.51 Million	52,955 Added 5.16%	1,078,722 $45.8 Million
Q3 2018 Nov 09, 2018	BUY	$47.1 - $62.7 $17.1 Million - $22.8 Million	363,728 Added 54.94%	1,025,767 $48.3 Million
Q2 2018 Aug 10, 2018	BUY	$26.05 - $52.4 $17.2 Million - $34.7 Million	662,039 New	662,039 $32.6 Million

Others Institutions Holding MRTX

# of Institutions

Shares Held

3.57M

Call Options Held

Put Options Held

36.6K

View Full List

About Mirati Therapeutics, Inc.

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

More about MRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Janus Henderson Group PLC with notifications on news.

Account